Nightingale’s analysis would fit that quite well, for the basic assessment https://stm.fi/-/hallitus-esittaa-mahdollisuutta-teknologia-avusteiseen-hoidon-tarpeen-arviointiin-perusterveydenhuollossa
6 Likes
I don’t think it’s about the same thing at all. A risk assessment for use in preventive healthcare is a completely different thing than assessing the need for treatment for an existing condition.
2 Likes
As I understand it, many people have existing ailments unknowingly (or a situation requiring treatment or at least lifestyle changes), and how better to screen for them (faster, cheaper) than with a blood test that reveals many hidden issues. I can’t say, though, how much a traditional-style blood test costs without the additional data provided by Nightingale.
That is true, and this is at the core of NGH. But this is not the assessment of the need for treatment that the linked government proposal concerns.
2 Likes
Excuse me, but what are the unnoticed existing ailments that Nightingale could reveal? Chest pain is an ailment, and the need for its treatment must be assessed. The LDL particle size revealed by Nightingale is not an unnoticed ailment whose need for treatment must be assessed.
An ailment is a different thing than a Nightingale measurement result.
1 Like
The company in question had a stand at the Helsinki Medical Convention this week, and interest seemed quite low. I did win a chocolate bar from the wheel of fortune, though.
In practice, they were lobbying doctors about a risk assessment taken from a single blood sample, which is “just as good as using the FINRISK or similar calculators that require more manual work”. It reportedly costs “a few tens” per patient, and the idea is that the doctor can get away with less work and can, for example, trigger statins onto the medication list if the indicators sound an alarm.
The idea of saving money is a challenging chapter (after all, this has to be justified to the buyers). In my opinion, however, the patient should still be seen, examined, and also interviewed a bit, so the doctor’s assessment cannot be removed from the equation. At the same time, you can also fill out the FINRISK and perhaps take other labs as well.
Still very skeptical about the company’s future.
3 Likes
I completely agree. The Finriski calculator takes as little time as calculating 2+2 on a calculator. And with its measurements, you know what to treat—for example, lowering cholesterol with statins or blood pressure with blood pressure medication.
With Nightingale, you get LDL particle sizes, and that information is useless in the real world.
In studies, the added value provided by Nightingale has been very modest and even harmful for the subjects.
1 Like
Don’t know about Doctors’ Days or anything, but FWD is showing strong growth, and Ng will be going full blast as a key driver in one category of their HealthyMe product going forward.. A couple of years old story, but the same rally likely continues..
They’ve been picking up all kinds of awards, too.
Roche and Ng probably aren’t competing with each other, but rather complement one another. At best, the NG product could significantly grow the bottom line in two ways – as a paid add-on service and through unrealized treatment costs. It’s an interesting position, even if the stock is currently languishing a bit.
Let’s post this more recent story from The Star if anyone missed it..
6 Likes
The public sector still has that downside where there needs to be solid evidence of the benefits. NG lacks evidence of health-promoting effects at a reasonable price.
In a week, there will be a Sitra event to launch a project that has been under preparation for a year:
The future of health data in the age of AI – national model launch event
Sunak will also be there sharing their insights on the panel.
22 Likes
There’s quite little buying interest in the air. There’s a risk that it will drift back toward the net cash level again, meaning prices well below one euro, if no news comes out.
It seems to have come down 40% in three months, without any real reason. In stocks like these, the decline tends to feed itself, so the trend will likely only break when the commercial leads are finalized. If it doesn’t happen this fiscal year (less than 6 months left), then it will never happen, one could assume.
1 Like
The reason is that the market price set by shareholders for the company is still one hundred million euros, for a company whose revenue is six million and loss is nearly twenty million.
So there is still plenty of room for a further decline.
7 Likes
Yeah, with that kind of selling pressure, many will soon take a massive hit on this.
Off to a great start, down about 15% from entry in three weeks. 
2 Likes
I hope we can get an analyst’s view on this; to a layman’s ears, it sounds like a big deal.
“Following a 2025 court decision in the United States, laboratory-developed tests (“LDTs”) will remain primarily under the CLIA/CLEP regulatory framework in the U.S. and will not be subject to regulation by the U.S. Food and Drug Administration (FDA). Nightingale Health is thus well-positioned after obtaining the CLEP permit, as a separate FDA approval for LDTs is not required.”
28 Likes
4 Likes
I certainly take this as clearly positive news; at least for me, it wasn’t a “foregone conclusion” that we wouldn’t end up in the FDA pipeline, as the company had communicated cautiously regarding the matter.
There are some quite interesting times ahead timing-wise; commercial prospects are developing on all continents but they take time… they could start materializing in parallel, which could lead to quite a ketchup bottle effect 
Well, let’s not get ahead of ourselves. Today, attention is also on that Sitra seminar to see if anything is heard regarding the domestic side…
1 Like
This Sitra development was news to me. Today is indeed the launch event for the national health data future model proposal, which is sold out.
That could very well be pro-Nightingale - we’ll wait for an announcement on the matter.
1 Like
It looks like the report was already published at 01:00. So, at a quick glance, there is a desire for a centralized system in Finland where national health data is collected in a standardized format. This certainly supports Nightingale’s operating model. Hopefully, the world follows in the same direction.
4 Likes